Adaptimmune Therapeutics (ADAP)
(Delayed Data from NSDQ)
$1.07 USD
-0.06 (-5.31%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $1.07 0.00 (0.00%) 7:02 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Adaptimmune Therapeutics PLC [ADAP]
Reports for Purchase
Showing records 61 - 80 ( 123 total )
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Biotechnology- Takeaways from Our Covered Companies at the 33rd ROTH Annual Conference
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
You Are Invited to Our Virtual 33rd Annual ROTH Conference on March 15-17, 2021
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Conclusive (and Inclusive) Quarterly Update For 3Q20
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
HiTting Solid Tumors with T-cell Therapy. R&D Day Top 10 Takeaways
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
3Q20 - Clinical Updates and Analyst Meeting Ahead
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Novel CD8 TCR May Have Higher Potency in Solid Tumors: SITC Abstract
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
SPEARHEAD 2 Design in Head and Neck Cancer at ESMO
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Healthcare -Strategies and Therapeutic Opportunities to Address Checkpoint (IO) Resistance
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Early Results of Therapy in Liver Cancer. Live or Die.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T